- Home
- TLRY vs FLGT Comparison
TLRY vs FLGT Comparison
Compare TLRY & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLRY
- FLGT
- Stock Information
- Founded
- TLRY N/A
- FLGT 2011
- Country
- TLRY Canada
- FLGT United States
- Employees
- TLRY N/A
- FLGT N/A
- Industry
- TLRY Medicinal Chemicals and Botanical Products
- FLGT Medical Specialities
- Sector
- TLRY Health Care
- FLGT Health Care
- Exchange
- TLRY Nasdaq
- FLGT Nasdaq
- Market Cap
- TLRY 637.2M
- FLGT 584.9M
- IPO Year
- TLRY 2018
- FLGT 2016
- Fundamental
- Price
- TLRY $0.43
- FLGT $19.70
- Analyst Decision
- TLRY Hold
- FLGT Buy
- Analyst Count
- TLRY 3
- FLGT 2
- Target Price
- TLRY $1.38
- FLGT $24.00
- AVG Volume (30 Days)
- TLRY 24.1M
- FLGT 386.6K
- Earning Date
- TLRY 04-08-2025
- FLGT 05-02-2025
- Dividend Yield
- TLRY N/A
- FLGT N/A
- EPS Growth
- TLRY N/A
- FLGT N/A
- EPS
- TLRY N/A
- FLGT N/A
- Revenue
- TLRY $826,656,000.00
- FLGT $292,448,000.00
- Revenue This Year
- TLRY $10.11
- FLGT $11.70
- Revenue Next Year
- TLRY $5.88
- FLGT $9.90
- P/E Ratio
- TLRY N/A
- FLGT N/A
- Revenue Growth
- TLRY 11.22
- FLGT 1.71
- 52 Week Low
- TLRY $0.41
- FLGT $14.57
- 52 Week High
- TLRY $2.31
- FLGT $25.11
- Technical
- Relative Strength Index (RSI)
- TLRY 34.40
- FLGT 58.66
- Support Level
- TLRY $0.41
- FLGT $18.42
- Resistance Level
- TLRY $0.52
- FLGT $20.94
- Average True Range (ATR)
- TLRY 0.03
- FLGT 0.86
- MACD
- TLRY 0.00
- FLGT 0.03
- Stochastic Oscillator
- TLRY 16.18
- FLGT 68.37
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.